Latest Dana-Farber Cancer Institute Stories
Although it sounds like a case of gender confusion on a molecular scale, the male hormone androgen spurs the growth of some breast tumors in women.
Mixed lineage leukemias rely on epigenetic changes to grow and survive; new molecule shows promise for targeting these changes therapeutically BOSTON, July 11, 2011 /PRNewswire-USNewswire/ -- A difficult-to-treat form of childhood leukemia relies on changes in the structure of DNA - so-called epigenetic changes - to wreak genomic havoc within white blood cells, according to one of two studies conducted by a research team at Children's Hospital Boston and Dana-Farber Cancer Institute.
WHITE PLAINS, N.Y., July 11, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is taking an aggressive and proactive approach to tackling the challenge of improving outcomes for cancer patients with particularly urgent needs.
Researchers at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.
BRAINTREE, Mass., June 15, 2011 /PRNewswire/ -- Herman Lowe, who has been battling terminal brain cancer, Glioblastoma, for over two years, has written a free online book, "Brain Cancer: Beating the Odds" about his journey and what he has done to try to help others with this deadly disease.
Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors.
AMSTERDAM and IRVINE, California, June 9, 2011 /PRNewswire/ -- Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center, one of the world's leading cancer centers and whose research program is considered one of the most productive in the world aimed solely at cancer, and the Netherlands Cancer Institute (NKI) with the aim of improving diagnosis and treatment...
A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas.
Scientists have identified an overactive network of genes that drive certain cancer cells enriched in triple-negative breast tumors.
Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies.
- A poem in which the author retracts something said in an earlier poem.